MYOCD

Across TCGA pan-cancer cohorts, MYOCD RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated MYOCD data layer compared with 9 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MYOCD RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MYOCD expression acts as an unfavorable survival marker, although some lineages such as KIRC and MESO show a favorable association.

KIRC, KIRP, and SCLC are the cancer types where MYOCD RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Quartile	III,IV	0.630	0.330	<.001	107	view →
KIRP	DFS	Tertile	All	0.539	0.821	<.001	97	view →
SCLC	OS	Tertile	II,III,IV	0.279	0.740	<.001	81	view →
MESO	DFS	Tertile	All	0.457	0.241	.004	56	view →
LUSC	OS	Quartile	All	0.320	0.526	.003	40	view →
UVM	DFS	Tertile	All	0.415	0.914	.004	35	view →
LIHC	DFS	Median	All	0.628	0.472	.003	29	view →
PRAD	DFS	Quartile	All	0.968	0.887	.006	18	view →
ACC	OS	Tertile	III,IV	0.919	0.420	.008	16	view →
LAML	DFS	Median	All	0.495	0.636	.023	16	view →
BRCA	DFS	Median	III,IV	0.931	0.819	.005	14	view →
CHOL	DFS	Median	All	0.858	0.128	.002	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

MYOCD–KIRC (DFS)

Open the KIRC breakdown →